Skip to main content


Hydroxybenzoic acid isomers and the cardiovascular system


Today we are beginning to understand how phytochemicals can influence metabolism, cellular signaling and gene expression. The hydroxybenzoic acids are related to salicylic acid and salicin, the first compounds isolated that have a pharmacological activity. In this review we examine how a number of hydroxyphenolics have the potential to ameliorate cardiovascular problems related to aging such as hypertension, atherosclerosis and dyslipidemia. The compounds focused upon include 2,3-dihydroxybenzoic acid (Pyrocatechuic acid), 2,5-dihydroxybenzoic acid (Gentisic acid), 3,4-dihydroxybenzoic acid (Protocatechuic acid), 3,5-dihydroxybenzoic acid (α-Resorcylic acid) and 3-monohydroxybenzoic acid. The latter two compounds activate the hydroxycarboxylic acid receptors with a consequence there is a reduction in adipocyte lipolysis with potential improvements of blood lipid profiles. Several of the other compounds can activate the Nrf2 signaling pathway that increases the expression of antioxidant enzymes, thereby decreasing oxidative stress and associated problems such as endothelial dysfunction that leads to hypertension as well as decreasing generalized inflammation that can lead to problems such as atherosclerosis. It has been known for many years that increased consumption of fruits and vegetables promotes health. We are beginning to understand how specific phytochemicals are responsible for such therapeutic effects. Hippocrates’ dictum of ‘Let food be your medicine and medicine your food’ can now be experimentally tested and the results of such experiments will enhance the ability of nutritionists to devise specific health-promoting diets.


The identification of salicin and salicylic acid as the chemical compounds that gave willow bark its analgesic and antipyretic properties initiated the development of the modern pharmaceutical industry and pharmaceuticals now dominate the therapeutic interventions of modern Western (allopathic) medicine. During the past few centuries there have been major breakthroughs in understanding the role of foods in the maintenance of life, including: i) the identification of carbohydrates, lipids and proteins and their roles in maintaining the metabolic machinery of our bodies, ii) the identification of vitamins and minerals and their roles in metabolism. The past century also led to major breakthroughs in understanding cellular signaling pathways and the control of gene expression. We are now beginning to understand how components in our foods, mainly certain phytochemicals, are affecting cellular signaling thereby influencing metabolism as well as gene expression. We are, thus, on the cusp of the third era of nutrition where we will understand the roles that particular phytochemicals can play in altering metabolism and gene expression that leads to better health [1]. In this review we consider the possible therapeutic effects of hydroxybenzoic acids that chemically are closely related to the first identified pharmaceuticals, salicin and salicylic acid. These compounds either decrease oxidative stress and inflammation through promotion of the expression of antioxidant enzymes or they inhibit adipocyte lipolysis through activation of hydroxycarboxylic acid receptors, thereby potentially promoting better plasma lipid profiles. Of course, everything is double-edged and phytochemicals may also affect the activity and/or expression of the phase 1 enzymes that metabolize xenobiotics, including drugs. The past has shown us that if one were taking the calcium channel blocker felodipine it becomes important for one’s health not to consume grapefruit [2]. Thus, if one were to alter diet to increase intake of particular phytochemicals, it becomes important to know how such phytochemicals affect the function of phase 1 enzymes.

A major aim of this review is to interest researchers in the area of nutrition to investigate how phytochemicals influence cellular signaling and gene expression so that rapid progress can be made in the science of Hippocrates’ dictum: ‘let food be your medicine and medicine your food’.


Discovery of salicin and salicylic acid

The first pharmacologically-active drugs isolated from a herbal preparation were identified during the nineteenth century [3]. These were the analgesics salicin (2-(hydroxymethyl)phenyl-β-D-glucopyranoside) and its metabolite salicylic acid (2-hydroxybenzoic acid) (Figure 1): these were obtained from willow bark extracts [3]. The analgesic and antipyretic activities of willow bark extracts were known far earlier, being mentioned in Egyptian and Sumerian texts [4]. During the latter part of the nineteenth century salicylic acid was acetylated to form the more gastrointestinal-friendly non-steroidal anti-inflammatory drug acetylsalicylic acid (ASA or 2-[acetyloxyl]benzoic acid), commonly referred to as aspirin. Although used since the end of the nineteenth century the mechanisms of action of aspirin were only beginning to be discovered in the 1970s where it was demonstrated that aspirin inhibited the action of cyclooxygenase (COX) thereby inhibiting the synthesis of pro-inflammatory eicosanoids [5]. More recently it has been shown that aspirin also promotes the acetylation of COX2 resulting in the promotion of the synthesis of 15-hydroxyeicosatetraenoic acid that is converted into the anti-inflammatory eicosanoid 15-epi-lipoxin A4 [6].

Figure 1

Structures of salicin, salicylic acid and acetylsalicylic acid (2-[acetyloxyl]-benzoic acid). Chemical diagrams taken from Wikimedia Commons.

Following the discovery of salicin and synthesis of aspirin a large pharmaceutical industry arose around the identification and isolation of the pharmacologically-active compounds present in herbal medicines, with often modification of such active compounds to form the drugs currently in clinical use. Soon pharmaceuticals dominated the therapeutic interventions of Western (allopathic) medicine. Forgotten was Hippocrates’ dictum: “Let food be your medicine and medicine your food”. This article is primarily aimed at discussing the possible roles of the isomers of dihydroxybenzoic acid, that are present in certain fruits and vegetables, in preventing cardiovascular diseases.

Pharmacologically active compounds in foods that we eat

Recently it has become recognized that pharmacologically active compounds are present not only in herbal products but also in many of our foods; hence, foods, in principle, could, as stated by Hippocrates, be used in preventing, if not treating, many diseases, particularly diseases related to lifestyle that become more common with age.

One of the earliest identified pharmacologically active components in food is the isothiocyanate sulforaphane, which is a metabolite of the sulforaphane glucosinolate, also known as glucoraphanin [7]. Sulforaphane glucosinolate is present in crucifers and is present in very high levels in broccoli sprouts of particular cultivars [8]. Sulforaphane is a very potent activator of nuclear factor (erythroid-derived-2)-like-2 [Nrf2]) [9] through oxidation of the thiols of the protein Kelch-ECH-Associated Protein 1 (Keap1) that normally sequesters Nrf2 in the cytoplasm [10]. Nrf2 promotes the expression of genes whose protein products either promote scavenging of oxidants or decrease the likelihood of oxidant production [11, 12]. A more oxidizing environment results in many physiological problems. For example, a more oxidizing environment results in readier activation of the transcription factor complex nuclear factor kappa B (NFκB) [13] that, in turn, promotes expression of pro-inflammatory genes.

Broccoli sprouts rich in sulforaphane glucosinolate have been shown to reduce oxidative stress and inflammation in hypertensive rats thereby promoting better endothelial function and lower blood pressure [14]. A similar effect is seen when rats are given sulforaphane by gavage [15], indicating that the health-promoting effects of broccoli sprouts is due to the sulforaphane metabolite of the glucosinolate rather than some other component that may be present. Furthermore, the less oxidative stress and inflammation in pregnant hypertensive rats fed with broccoli sprouts results in less oxidative stress, inflammation and elevated blood pressure in the offspring even when the offspring do not have a diet rich in Nrf2 activators [16]. Thus, diet can have positive effect on fetal determinants of adult health. We, clearly, are now in the third era of nutritional research and are beginning to understand how specific phytochemicals affect cell signaling and gene expression and, thereby, health [1].

A concern may arise whether the increase in consumption of foods that have increased Nrf2 activity may be harmful. As far as sulforaphane glucosinolate is concerned phase 1 clinical trials in human have indicated no ontoward effect on liver and thyroid function when ingesting broccoli sprout extracts rich in sulforaphane glucosinolate [17]. Furthermore, another human trial in type 2 diabetics has shown that consuming a broccoli sprout extract containing either 112.5 or 225 micromoles of sulforaphane glucosinolate significantly decreased fasting glucose and insulin levels [18], demonstrating that food sources can be used as a medicine. Finally, the Juurlink laboratory has shown that intake of 10 μmol sulforaphane/kg body weight by gavage for 4 months had no detectable negative effect on the Stroke-prone spontaneously hypertensive rats [15], nor did consumption of broccoli sprouts containing 5–10 μmol sulforaphane equivalents/Kg body weight have any effect on the normal physiology Sprague Dawley rats [14]; thus, compounds that are Nrf2 activators appear to have physiological effects only in individuals that are under oxidative stress. Intake of sulforaphane tips the cell to a more normal redox state thereby decreasing the probability of problems related to inflammation. For a more detailed look at how the Nrf2 system influences cardiovascular health, please see [12].

Surprisingly, although there are over a thousand papers examining the positive effects of sulforaphane in preventing cancer, treating cancer, decreasing oxidative stress or treating conditions with an underlying oxidative stress and inflammatory component, there are no toxicology studies reported for this compound. Sulforaphane is an electrophile and like other electrophiles it oxidizes thiols. However, unlike other electrophiles such as dimethyl fumarate, sulforaphane - as well as certain other phytochemicals - has the particular electro-geometry that allows oxidation of Keap1 thiols at submicromolar concentrations. Thus, 50 nM sulforaphane has the same ability to increase Nrf2-inducible protein expression [19] as 25 μM dimethyl fumarate [20]: in other words, 500 times as many thiols are oxidized by dimethyl fumarate, a drug recently approved as a treatment for multiple sclerosis [21], to obtain the same Nrf2 activation as 50 nM sulforaphane.

Keap1 thiols are not the only thiols oxidized by sulforaphane and one might anticipate that sulforaphane ought to interfere with many cellular functions. In an attempt to address this, Piberger and colleagues examined the ability of sulforaphane to release zinc from a synthetic peptide that resembled the zinc-binding domain of xeroderma pigmentosum A [22]. They demonstrated that sulforaphane at concentrations of 50 μM or greater caused zinc release from the peptide; however, they also demonstrated that lower levels of sulforaphane (5 μM) interfered with the xeroderma pigmentosum A-dependent nucleotide excision repair. It is unlikely that plasma levels of sulforaphane can reach 5 μM through dietary intake of sulforaphane glucosinolate. Indeed, male spontaneously hypertensive stroke-prone rats fed daily a dried broccoli sprouts containing 14.5 micromoles of sulforaphane equivalent only achieved a plasma level of 0.5 μM dithiocarbamate [23], the sulforaphane metabolite. One must also keep in mind that unlike in cell culture studies where there is a constant concentration of the compound of interest, dietary intake of sulforaphane, whether through food consumption or through gavage, results in fluctuating plasma levels where peak concentrations can result in sustained elevations of anti-oxidant proteins through activation of the Nrf2 system but only transient inactivation of the function of proteins such as xeroderma pigmentosum A. Clearly, there is an abundance of evidence, both epidemiological and experimental that is in support of the ability of sulforaphane’s health-promoting activities [24].

Concerns with increasing consumption of pharmacologically active compounds found in our foods

The knowledge of which particular cultivar one is consuming can be important. For example, various cultivars of broccoli and other crucifers have different glucosinolate profiles and a major concern with glucosinolates is that some of them are goitrogenic [25]; hence, it is important to ensure that one is increasing sulforaphane glucosinolate consumption that one does not consume significant quantities of goitrogenic glucosinolates. In the studies by the Juurlink laboratory the Calabrese variety of broccoli was used since this cultivar has high levels of sulforaphane glucosinolate and other Nrf2-activating glucosinolates but low levels of the goitrogenic glucosinolates [14].

Phytochemical compounds may have more than one mechanism of action. Another major concern is effects of phytochemicals on the expression and/or activity of the drug metabolizing phase 1 enzymes, for example, the cytochrome P450s (CYPs). Altering phase 1 enzyme activity can affect drug metabolism. For example, the flavanone naringenn activates Nrf2 [26] but it is also a competitive inhibitor of CYP3A4 [27]. CYP3A4 is involved in the metabolism of many commonly used drugs. For example, CYP3A4 is involved in the metabolism of felodipine, a calcium channel blocker [28]. If one is taking felodpine, consuming increased amounts of naringenin and furanocoumarins present in grapefruit juice may cause dangerous elevations in the plasma level of felodipine resulting in dangerously low blood pressure. Other Nrf2 activators, such as sulforaphane, also have effects on phase 1 enzyme expression or activity [29], for example, sulforaphane inhibits CYP3A4 gene expression and inhibits CYP1A2 and CYP2E1 [30]. Clearly, if one is on a medication it becomes important to know the effects of consuming increasing amounts of foods with pharmacologically active components. Physicians are already aware that when administering the vitamin K epoxide reductase inhibitor warfarin, that the dosage required for the desired pharmacological effect is dependent upon dietary intake of green leafy vegetables that are rich in vitamin K [31]. Thus, altering diet to increase intake of phytochemicals that are pharmacologically active will make the life of a physician or nutritionist more complicated.

The hydroxybenzoic acids

It is 185 years since Henri Leroux first isolated a pure crystalline form of salicin [3]. It seems timely to revisit this family of hydroxyphenols in the context of human health. There are a number of dihydroxybenzoic acid (DHBA) compounds, related to salicylic acid, that are also pharmacologically active, some of which are metabolites of salicylic acid. Their chemical formulae are outlined in [32] and given in Figure 2. The compounds include 2,3-DHBA (Pyrocatechuic acid or Hypogallic acid), 2,5-DHBA (Gentisic acid), 2,4-DHBA (β-Resorcylic acid), 2,6-DHBA (γ-Resorcylic acid), 3,4-DBHA (Protocatechuic acid) and 3,5-DHBA (α-Resorcylic acid) [32, 33]. The hydroxybenzoic acids are phytochemicals that can be found in certain of foods and can be also be formed from polyphenols such as flavonoids by gut bacteria, e.g., [34]. Because they are hydroxylated phenolic compounds they all can scavenge oxidants such as free radicals via their hydroxyl groups [35], but this is not an important mechanism of action since essentially one hydroxylated phenolic compound can scavenge only one or two strong oxidants. Their more interesting properties are associated with their ability to modify cellular signaling processes that introduces a multiplier effect, one example is activation of the Nrf2 pathway that results in enhancement of multiple endogenous anti-oxidant mechanisms. We will focus on a few of these hydroxyphenolic compounds in this review.

Figure 2

Structures of the isomers of dihydroxybenzoic acid. Chemical diagrams taken from Wikimedia Commons.

2,3-DHBA (Pyrocatechuic acid)

Pyrocatechuic acid is a metabolite of aspirin [33]. It is normally present in plasma even when there has been no intake of aspirin [36], indicating a dietary source of either 2,3-DHBA or a precursor molecule. 2,3-DHBA is present in several medicinal herbs, including, Madagascar rosy periwinkle [37] and Boreava orientalis[38] as well as in a number of fruits such as batoko plum commonly made into preserves in South and South-East Asia [39], avocados [40] and cranberries [41, 42]. A major dietary source of pyrocatechuic acid is Aspergillus-fermented soy products, popular in Japan, that can contain more than 2 mmol 2,3-DHBA/L soy product [43].

2,3-DHBA decreases hydrogen peroxide-induced activation of the transcription factor complex nuclear factor kappa B (NFκB) that plays an important role in inflammation [44]. The mechanism of action for this effect may be simple scavenging of hydrogen peroxide [35] or possibly the activation of the antioxidant response; however, this latter mechanism of action has not been examined in this hydroxybenzoic acid metabolite, although other dihydroxybenzoic acids have this ability. Nor has there been examination of the possible effects of 2,3-DHBA on phase 1 enzyme expression and activity. Administration of 2,3-DHBA to a rat model of sepsis has been reported to decrease mortality when used in conjunction with gentamycin [45], likely through decreased tissue damage related to oxidative stress and associated inflammation. Relatively little is known about the distribution of 2,3-DHBA in the plant kingdom nor its mechanism of therapeutic action but both seem worthy of further investigation.

2,5-DHBA (gentisic acid)

Gentisic acid like aspirin inhibits prostaglandin formation in response to lipopolysaccharides [46], presumably via inhibiting COX activity. This suggests that foods rich in gentisic acid may help decrease the probability of heart attacks due to clot formation. Gentisic acid also inhibits the oxidation of low-density lipoprotein and inhibits the formation of lipid hydroperoxides [47, 48] and, thus, decreases the probability of atherogenesis. These effects of gentisic acid are usually attributed to its ability to scavenge free radicals and other oxidants; however, gentisic acid is also an Nrf2 activator [49] and this is the most likely relevant mechanism. In the study by Yeh and Yen [49], gentisic acid was introduced into the diet whereby rats consumed very high amounts of gentisic acid (650 μmol/Kg/day) - what plasma levels were achieved was not measured. Clearly, dose–response studies are required to determine whether gentisic acid activates the Nrf2 system at much lower dietary intakes. Also, at high concentrations gentisic acid is an aldose reductase inhibitor but the IC50 is over 200 μM [50], concentrations that are likely not attainable via the diet. How, and whether, gentisic acid affects phase 1 enzyme gene expression and activity is not known. CYP2E1 and CYP3A4 are involved in the metabolism of gentisic acid [51].

Gentisic acid is widely present in foods we consume, including cereals such as wheat and rye [52], actinidia (e.g., kiwi) fruit [53], aloe vera [54], a number of mushrooms [55] as well as other sources. For quantitative data on gentisic acid distribution in food sources see Table 1.

Table 1 Dietary sources of gentisic acid

3,4-DHBA (protocatechuic acid)

Protocatechuic acid is widely distributed, in our foods being found in buckwheat [62], mustard [63], nipa palm nut [64], kiwi fruit [65], currents [66], blackberries and strawberries [67], Jujube fruit [68], chokeberries [69], mango [70]. In addition, it is also found in chicory, olives, dates, grapes, cauliflower, lentils, etc. [71]. For quantitative data on protocatechuic acid in food sources see Table 2.

Table 2 Dietary sources of protocatechuic acid

Protocatechuic acid has anti-inflammatory activity [71] and activates Nrf2 [69] through Jun kinase (JNK) modification of the Nrf2 signalling system [83]. In this in vitro study, 25 μM protcatechuic acid was used. However, a lower concentration (3 μM) demonstrated an enhancement in the antioxidant defense systems [84]. In another in vitro assay the concentration of protocatechuic acid required to double the quinone oxireductase activity in murine hepatoma cells was 4.3 μM [69]. These studies suggest that diet may result in plasma protcatechuic acid levels sufficient to enhance the antioxidant defense systems. Protocatechuic acid also has antihyperglycemic effects in streptozotocin-induced diabetic rats [85], possibly through activation of the Nrf2 system. For a detailed discussion on the potential role of protocatechuic acid in preventing disease or treating disease see [71].

3-Monohydroxybenzoic Acid (3-MHBA) and 3,5-Dihydroxybenzoic Acid (α-Resorcylic Acid)

The final compounds to be considered are 3-MHBA (also known as m-hydroxybenzoic acid) and 3,5-DHBA since there is an intriguing article demonstrating that they are agonists of the hydroxycarboxylic acid receptors HCA1 and HCA2[86]. The HCA receptor family is G-protein coupled (Gi) and comprised of three members: HCA1, HCA2 and HCA3[86] predominantly expressed on adipocytes. Activation of HCA receptors inhibits lipolysis. They were formerly classified within the nicotinic acid receptor family. The natural ligand for HCA1 appears to be lactic acid (EC50 = 1.3-4.8 mM) whose normal plasma concentrations (in low mM range) can activate HCA1 to decrease lipolysis. The natural ligand for HCA2 is 3-hydroxybutyric acid (EC50 = 0.7-0.8 mM) whose plasma levels can reach 6–8 mM during fasting. Nicotinic acid also acts as a ligand for HCA2 and has been used pharmacologically to treat dyslipidemia [87], although it has an associated flushing problem. The natural ligand for HCA3 is 3-hydroxyoctanoic acid (EC50 = 4–8 μM) whose levels rise during starvation and diabetic ketosis [86]. These receptors are, thus, intimately involved in the feedback mechanisms regulating lipolysis.

3-MHBA is an agonist for both HCA1 (EC50 of 186 μM) and HCA2 (EC50 of 158 μM while 3,5-DHBA is a specific agonist for HCA2 (EC50 of 172 μM). Activating HCA1 and HCA2 inhibits lipolysis in adipocytes [86]. These data suggest that altering diet to include 3-MHBA and/or 3,5-DHBA may help control dyslipedemia. However, little information is available regarding the presence of these hydroxybenzoic acid compounds in the plants we eat. A little more is known about 3-MHBA (see Table 3) than 3,5-DHBA.

Table 3 Dietary sources of 3-monohydroxybenzoic acid

Important sources of hydroxybenzoic acids are microbial metabolites of more complex phenolics

Zhang and colleagues used a commercial cranberry drink to determine the proportion of dietary phenolics transferred to the blood [41]. The cranberry drink was comprised of 27% juice and contained 2.41 μg 2,3-DHBA/mL [41] with a total of 1800 mL consumed by each test subject (i.e., a total of 438 μg or 2.84 μmoles 2,3-DHBA). After 45 minutes blood was taken and plasma level of phenolics were determined. At this time plasma levels of 2,3-DHBA was 2.06 μg/mL. Even if the 2,3-DHBA was solely restricted to plasma and not cells or other body fluids, this is a greater amount of 2,3-DHBA than what was consumed. One can only conclude that there is metabolism of other phenolics to 2,3-DHBA, likely by gut bacteria. Indeed, there is an abundance of evidence that gut bacteria metabolize more complex phenolics such as flavonoids into simpler phenolics [88].

Another example is 3,4-DHBA (protocatechuic acid) which can be an oxidation product of the flavonoid quercetin [89] as well as a microbial metabolite of catechin [90] and anthocyanins and procyanidins [91]. Humans fed 60 g/day of a black raspberry freeze-dried powder, rich in anthocyanins, achieved a mean protocatechuic acid plasma level of 25 nM [92]. In another study where human participants ate two portions of a variety of small berries daily achieved mean protcatechuic acid plasma levels of 130 nM [93]. A third study where elderberry extract containing a total of 500 mg anthocyanins was consumed daily, protocatechuic sulfate plasma levels reached 360 nM three hr after intake [94]. A fourth study had humans consume 1 liter of blood orange juice rich in cyanidin glucosides - here a plasma level of 0.5 μM protocatechuic acid was observed 2 hr following ingestion [91]. Whether intake of protocatechuic acid via the diet will result in sufficient plasma concentrations to have a pharmacological effect is not yet demonstrated, but as noted below perhaps it can have a tipping effect.

Phytochemicals as tipping point compounds rather than pharmaceuticals

Disease is a deviation from homeostasis. In a ‘normal’ diet it is rare that one can consume enough of a given food to achieve a plasma concentration of a specific compound of interest to have a pharmacologically significant effect. However, one must keep in mind that we are constantly consuming foods that have more than one of these compounds that can affect, for example, the Nrf2 system. An increase in the consumption of anyone of these may be the tipping point to activate the Nrf2 system sufficiently to result in cells with a more normalized redox status. For example, for Nrf2 to translocate from the cytoplasm to the nucleus requires oxidation of thiols on Kelch-like ECH-associated protein-1 (Keap1), the protein that anchors Nrf2 to the cytoskeleton, but the phosphorylation status of particular amino acid residues on Nrf2 also determines the efficacy of nuclear translocation [95]. The action of sulforaphane is oxidation of Keap1 thiols [96], whereas the action of protocatechuic acid is on the phosphorylation status of Nrf2 [83]. Thus, protocatechuic acid will enhance the efficacy of low levels of an inducer such as sulforaphane. It may well be possible that on a background of a diet containing low levels of sulforaphane glucosinolate (that in itself has no significant effect on the activation of the Nrf2 system) that consuming low levels of protocatechuic acid may be the tipping point towards activation (i.e., nuclear translocation) of the Nrf2 system resulting in a more normal redox state for cells.

Similarly, the EC50s of 3-MHBA for HCA1 and 3,5-DHBA for HCA2 suggest that diet cannot influence the activation state of these hydroxycarboxylic acid receptors. Although the EC50 is an important measure of activity since it is a measure of the concentration where 50% of the receptors are activated, it is not a measure of the kinetics of the binding. Importantly it does not measure the time a compound occupies and activates the receptor. If, for example, the 3,5-DHBA-HCA2 dissociation time is significantly longer than the lactate-HCA2 dissociation time, then this effectively lowers that lactate concentration necessary to activate the HCA2 signalling pathway. It is very possible that concentrations of the hydroxycarboxylic acid an order or two below the EC50 will allow lower concentrations of the natural ligand to result in physiologically significant increases in receptor activation states to result in decreases in lipolysis to significantly affect blood lipid levels. In other words dietary intake of 3-MHBA and 3,5-DHBA that result in low μmolar plasma concentrations may tip the scale towards more normal lipid profiles.

Concluding remarks

We are now at the knowledge tipping point where rather than having vague guides on eating more fruits and vegetables to improve health we can design diets to include specific phytochemicals that influence cellular signaling and gene expression. For example, diets containing specific Nrf2 activators that act on Keap1 thiols as well as activators that act on the phosphorylation states of Nrf2 allowing more efficient Nrf2 translocation to the nucleus - the end result is a more normal redox status of cells with consequences that include decreased probabilities of developing hypertension and developing atherosclerotic lesions. We can design diets that increase the content of 3-MHBA and/or 3,5-DHBA that results in tipping to a more normal blood lipid profile, again decreasing the probability of developing atherosclerotic lesions. We are at the beginning of understanding how phytochemicals may influence signaling pathways that influence cardiovascular health. We trust we have intrigued the readers sufficiently to do further research on the distribution, microbial metabolism and uptake of hydroxybenzoic acids as well as on their potential therapeutic actions.

Authors’ information

Dr P. Ganguly (MBBS, MD, FACA) has spent many years in catecholamine research in health and disease. He worked earlier with metabolites of catecholamines and found that oxidation products such as adrenochrome may be detrimental to cardiac function. B.H.J. Juurlink (PhD) has spent many years examining how cellular redox influences inflammation and how phytochemicals can promote a more normal redox environment through Nrf2 activation thereby decreasing aging-associated problems such as hypertension and generalized inflammation. Ms Azouz, Ms Aldalati and Ms AlTinawi are second year medical students with an interest in how dietary phytochemicals may influence health.





Cytochrome P450


Dihydroxybenzoic acid


3-DHBA: 2,3-Dihydroxybenzoic acid


4-DBHA: 2,4-Dihydroxybenzoic acid


5-DHBA: 2,5-Dihydroxybenzoic acid


6-DHBA: 2,6-Dihydroxybenzoic acid


4-DHBA: 3,4-Dihydroxybenzoic acid


5-DHBA: 3,5-Dihydroxybenzoic acid

EC50 :

Half-maximal effective concentration

Gi :

Guanosine-nucleotide-binding protein alpha inhibitory


Guanosine nucleotide-binding protein


Hydroxycarboxylic acid receptor


3-Monohydroxybenzoic acid








Nuclear factor kappa B


Nuclear factor (erythroid-derived-2)-like-2.


  1. 1.

    Juurlink BHJ: The beginning of the nutri-geno-proteo-metabolo-mics era of nutritional studies. National Research Council of Canada PBI Bulletin, Issue 1. Plants That Heal. 2003, 9-13.

  2. 2.

    Bressler R: Grapefruit juice and drug interactions. Exploring mechanisms of this interaction and potential toxicity for certain drugs. Geriatrics. 2006, 61: 12-18.

  3. 3.

    Mahdi JG, Mahdi AJ, Mahdi AJ, Bowen ID: The historical analysis of aspirin discovery, its relation to the willow tree and antiproliferative and anticancer potential. Cell Prolif. 2006, 39: 147-155.

  4. 4.

    Lévesque H, Lafont O: L’aspirine à travers les siècles: rappel historique. Rev Med Interne. 2000, 21: 8-17.

  5. 5.

    Vane JR, Botting RM: The mechanism of action of aspirin. Thromb Res. 2003, 110: 255-258.

  6. 6.

    Chiang N, Serhan CN: Aspirin triggers formation of anti-inflammatory mediators: New mechanism for an old drug. Discov Med. 2004, 4: 470-475.

  7. 7.

    Zhang Y, Talalay P, Cho CG, Posner GH: A major inducer of anticarcinogenic protective enzymes from broccoli: isolation and elucidation of structure. Proc Natl Acad Sci U S A. 1992, 89: 2399-2403.

  8. 8.

    Fahey JW, Zhang Y, Talalay P: Broccoli sprouts: an exceptionally rich source of inducers of enzymes that protect against chemical carcinogens. Proc Natl Acad Sci U S A. 1997, 94: 10367-10372.

  9. 9.

    Dinkova-Kostova AT, Holtzclaw WD, Cole RN, Itoh K, Wakabayashi N, Katoh Y, Yamamoto M, Talalay P: Direct evidence that sulfhydryl groups of Keap1 are the sensors regulating induction of phase 2 enzymes that protect against carcinogens and oxidants. Proc Natl Acad Sci U S A. 2002, 99: 11908-11913.

  10. 10.

    Kensler TW, Egner PA, Agyeman AS, Visvanathan K, Groopman JD, Chen JG, Chen TY, Fahey JW, Talalay P: Keap1-nrf2 signaling: a target for cancer prevention by sulforaphane. Top Curr Chem. 2013, 329: 163-177.

  11. 11.

    Juurlink BH: Therapeutic potential of dietary phase 2 enzyme inducers in ameliorating diseases that have an underlying inflammatory component. Can J Physiol Pharmacol. 2001, 79: 266-282.

  12. 12.

    Juurlink BH: Dietary Nrf2 activators inhibit atherogenic processes. Atherosclerosis. 2012, 225: 29-33.

  13. 13.

    Christman JW, Blackwell TS, Juurlink BH: Redox regulation of nuclear factor kappa B: therapeutic potential for attenuating inflammatory responses. Brain Pathol. 2000, 10: 153-162.

  14. 14.

    Wu L, Noyan Ashraf MH, Facci M, Wang R, Paterson PG, Ferrie A, Juurlink BH: Dietary approach to attenuate oxidative stress, hypertension, and inflammation in the cardiovascular system. Proc Natl Acad Sci U S A. 2004, 101: 7094-7099.

  15. 15.

    Senanayake GV, Banigesh A, Wu L, Lee P, Juurlink BH: The dietary phase 2 protein inducer sulforaphane can normalize the kidney epigenome and improve blood pressure in hypertensive rats. Am J Hypertens. 2012, 25: 229-235.

  16. 16.

    Noyan-Ashraf MH, Wu L, Wang R, Juurlink BH: Dietary approaches to positively influence fetal determinants of adult health. FASEB J. 2006, 20: 371-373.

  17. 17.

    Shapiro TA, Fahey JW, Dinkova-Kostova AT, Holtzclaw WD, Stephenson KK, Wade KL, Ye L, Talalay P: Safety, tolerance, and metabolism of broccoli sprout glucosinolates and isothiocyanates: a clinical phase I study. Nutr Cancer. 2006, 55: 53-62.

  18. 18.

    Bahadoran Z, Tohidi M, Nazeri P, Mehran M, Azizi F, Mirmiran P: Effect of broccoli sprouts on insulin resistance in type 2 diabetic patients: a randomized double-blind clinical trial. Int J Food Sci Nutr. 2012, 63: 767-771.

  19. 19.

    Wu L, Juurlink BH: The impaired glutathione system and its up-regulation by sulforaphane in vascular smooth muscle cells from spontaneously hypertensive rats. J Hypertens. 2001, 19: 1819-1825.

  20. 20.

    Spencer SR, Wilczak CA, Talalay P: Induction of glutathione transferases and NAD(P)H:quinone reductase by fumaric acid derivatives in rodent cells and tissues. Cancer Res. 1990, 50: 7871-7875.

  21. 21.

    Burness CB, Deeks ED: Dimethyl fumarate: a review of its use in patients with relapsing-remitting multiple sclerosis. CNS Drugs. 2014, 28: 373-387.

  22. 22.

    Piberger AL, Koberle B, Hartwig A: The broccoli-born isothiocyanate sulforaphane impairs nucleotide excision repair: XPA as one potential target. Arch Toxicol. 2014, 88: 647-658.

  23. 23.

    Facci MR: The Effect of a Dietary Phase 2 Protein Inducer on Inflammatory Parameters in Blood and Liver of Spontaneously Hypertensive Stroke-Prone Rats. 2004, Department of Anatomy & Cell Biology: Master’s University of Saskatchewan

  24. 24.

    Clarke JD, Dashwood RH, Ho E: Multi-targeted prevention of cancer by sulforaphane. Cancer Lett. 2008, 269: 291-304.

  25. 25.

    Fahey JW, Zalcmann AT, Talalay P: The chemical diversity and distribution of glucosinolates and isothiocyanates among plants. Phytochemistry. 2001, 56: 5-51.

  26. 26.

    Gopinath K, Sudhandiran G: Naringin modulates oxidative stress and inflammation in 3-nitropropionic acid-induced neurodegeneration through the activation of nuclear factor-erythroid 2-related factor-2 signalling pathway. Neuroscience. 2012, 227: 134-143.

  27. 27.

    Ho PC, Saville DJ, Wanwimolruk S: Inhibition of human CYP3A4 activity by grapefruit flavonoids, furanocoumarins and related compounds. J Pharm Pharm Sci. 2001, 4: 217-227.

  28. 28.

    Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR: Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther. 2000, 68: 468-477.

  29. 29.

    Gross-Steinmeyer K, Stapleton PL, Liu F, Tracy JH, Bammler TK, Quigley SD, Farin FM, Buhler DR, Safe SH, Strom SC, Eaton DL: Phytochemical-induced changes in gene expression of carcinogen-metabolizing enzymes in cultured human primary hepatocytes. Xenobiotica. 2004, 34: 619-632.

  30. 30.

    Fimognari C, Lenzi M, Hrelia P: Interaction of the isothiocyanate sulforaphane with drug disposition and metabolism: pharmacological and toxicological implications. Curr Drug Metab. 2008, 9: 668-678.

  31. 31.

    Booth SL, Centurelli MA: Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev. 1999, 57: 288-296.

  32. 32.

    Liu D, Su Z, Wang C, Gu M: Separation of five isomers of dihydroxybenzoic acid by high-speed counter-current chromatography with dual-rotation elution method. J Chromatogr Sci. 2009, 47: 345-348.

  33. 33.

    Grootveld M, Halliwell B: 2,3-Dihydroxybenzoic acid is a product of human aspirin metabolism. Biochem Pharmacol. 1988, 37: 271-280.

  34. 34.

    Jiang S, Yang J, Qian D, Guo J, Shang EX, Duan JA, Xu J: Rapid screening and identification of metabolites of quercitrin produced by the human intestinal bacteria using ultra performance liquid chromatography/quadrupole-time-of-flight mass spectrometry. Arch Pharm Res. 2014, 37: 204-213.

  35. 35.

    Sroka Z, Cisowski W: Hydrogen peroxide scavenging, antioxidant and anti-radical activity of some phenolic acids. Food Chem Toxicol. 2003, 41: 753-758.

  36. 36.

    Paterson JR, Blacklock C, Campbell G, Wiles D, Lawrence JR: The identification of salicylates as normal constituents of serum: a link between diet and health?. J Clin Pathol. 1998, 51: 502-505.

  37. 37.

    Muljono RA, Darsono FL, Scheffer JJ, Verpoorte R: Assay of 2,3-dihydroxybenzoic acid and related compounds in plant materials by high-performance liquid chromatography. J Chromatogr A. 2001, 927: 39-45.

  38. 38.

    Sakushima A, Coskun M, Maoka T: Hydroxybenzoic acids from Boreava orientalis. Phytochemistry. 1995, 40: 257-261.

  39. 39.

    Shibumon G, Benny PJ, Kuriakose S, Cincy G: Antibiotic acivity of 2,3-dihydroxybenzoic acid isolated from Flacourtia inermis fruit against multidrug resistant bacteria. Asian J Pharm Clin rese. 2011, 4: 126-130.

  40. 40.

    Torres AM, Maulastovicka T, Rezaaiyan R: Total Phenolics and high-performance liquid chromatography of phenolic acids of avocado. J Agr Food Chem. 1987, 35: 921-925.

  41. 41.

    Zhang K, Zuo Y: GC-MS determination of flavonoids and phenolic and benzoic acids in human plasma after consumption of cranberry juice. J Agric Food Chem. 2004, 52: 222-227.

  42. 42.

    Zuo Y, Wang C, Zhang J: Separation, Characterization, and quantitation of benzoic and phenolic antioxidants in American cranberry fruit by GC-MS. J Agr Food Chem. 2002, 50: 3789-3794.

  43. 43.

    Esaki H, Onozaki H, Kawakishi S, Osawa T: Antioxidant activity and isolation from soybeans fermented with Aspergillus spp. J Agr Food Chem. 1997, 45: 2020-2024.

  44. 44.

    Sappey C, Boelaert JR, Legrand-Poels S, Grady RW, Piette J: NF-kappa B transcription factor activation by hydrogen peroxide can be decreased by 2,3-dihydroxybenzoic acid and its ethyl ester derivative. Arch Biochem Biophys. 1995, 321: 263-270.

  45. 45.

    Pearce RA, Finley RJ, Mustard RA, Duff JH: 2,3-Dihydroxybenzoic acid. Effect on mortality rate in a septic rat model. Arch Surg. 1985, 120: 937-940.

  46. 46.

    Hinz B, Kraus V, Pahl A, Brune K: Salicylate metabolites inhibit cyclooxygenase-2-dependent prostaglandin E(2) synthesis in murine macrophages. Biochem Biophys Res Commun. 2000, 274: 197-202.

  47. 47.

    Ashidate K, Kawamura M, Mimura D, Tohda H, Miyazaki S, Teramoto T, Yamamoto Y, Hirata Y: Gentisic acid, an aspirin metabolite, inhibits oxidation of low-density lipoprotein and the formation of cholesterol ester hydroperoxides in human plasma. Eur J Pharmacol. 2005, 513: 173-179.

  48. 48.

    Exner M, Hermann M, Hofbauer R, Kapiotis S, Speiser W, Held I, Seelos C, Gmeiner BM: The salicylate metabolite gentisic acid, but not the parent drug, inhibits glucose autoxidation-mediated atherogenic modification of low density lipoprotein. FEBS Lett. 2000, 470: 47-50.

  49. 49.

    Yeh CT, Yen GC: Induction of hepatic antioxidant enzymes by phenolic acids in rats is accompanied by increased levels of multidrug resistance-associated protein 3 mRNA expression. J Nutr. 2006, 136: 11-15.

  50. 50.

    Lee SJ, Park WH, Park SD, Moon HI: Aldose reductase inhibitors from Litchi chinensis Sonn. J Enzyme Inhib Med Chem. 2009, 24: 957-959.

  51. 51.

    Dupont I, Berthou F, Bodenez P, Bardou L, Guirriec C, Stephan N, Dreano Y, Lucas D: Involvement of cytochromes P-450 2E1 and 3A4 in the 5-hydroxylation of salicylate in humans. Drug Metab Dispos. 1999, 27: 322-326.

  52. 52.

    Zhu Y, Shurlknight KL, Chen X, Sang S: Identification and pharmacokinetics of novel alkylresorcinol metabolites in human urine, new candidate biomarkers for whole-grain wheat and rye intake. J Nutr. 2014, 144: 114-122.

  53. 53.

    Latocha P, Krupa T, Wolosiak R, Worobiej E, Wilczak J: Antioxidant activity and chemical difference in fruit of different Actinidia sp. Int J Food Sci Nutr. 2010, 61: 381-394.

  54. 54.

    Lopez A, de Tangil MS, Vega-Orellana O, Ramirez AS, Rico M: Phenolic constituents, antioxidant and preliminary antimycoplasmic activities of leaf skin and flowers of Aloe vera (L.) Burm. f. (syn. A. barbadensis Mill.) from the Canary Islands (Spain). Molecules. 2013, 18: 4942-4954.

  55. 55.

    Karaman M, Stahl M, Vulic J, Vesic M, Canadanovic-Brunet J: Wild-growing lignicolous mushroom species as sources of novel agents with antioxidative and antibacterial potentials. Int J Food Sci Nutr. 2013, 65: 311-319.

  56. 56.

    Russell WR, Labat A, Scobbie L, Duncan GJ, Duthie GG: Phenolic acid content of fruits commonly consumed and locally produced in Scotland. Food Chem. 2009, 115: 100-104.

  57. 57.

    Floridi S, Montanari L, Marconi O, Fantozzi P: Detrmination of free phenolic acids in wort and beer by coulometric array detection. J Agr Food Chem. 2003, 51: 1548-1554.

  58. 58.

    Zadernowski R, Naczk M, Nesterowicz J: Phenolic acid profiles in some small berries. J Agr Food Chem. 2005, 53: 2118-2124.

  59. 59.

    Horax R, Hettiarachchy N, Chen P: Extraction, quantification, and antioxidant activities of phenolics from pericarp and seeds of bitter melons (Momordica charantia) harvested at three maturity stages (Immature, Mature, and ripe). J Agr Food Chem. 2010, 58: 4428-4433.

  60. 60.

    Ayaz FA, Hayirlioglu-Ayaz A, Gruz J, Novak O, Strnad M: Separation, characterization, and quantitation of phenolic acids in a little known blueberry (Vaccinium arctostaphylos L.) fruit by HPLC-MS. J Agr Food Chem. 2005, 53: 8116-8122.

  61. 61.

    Soleas GJ, Dam J, Carey M, Goldberg DM: Toward fingerprinting of wines: Cultivar-related patterns of polyphenolic constituents in Ontario Wines. J Agr Food Chem. 1997, 45: 3871-3880.

  62. 62.

    Sedej I, Sakac M, Mandic A, Misan A, Tumbas V, Canadanovic-Brunet J: Buckwheat (Fagopyrum esculentum Moench) grain and fractions: antioxidant compounds and activities. J Food Sci. 2012, 77: C954-C959.

  63. 63.

    Li C, Tang Z, Huang M, Tao N, Feng B, Huang S: Antioxidant efficacy of extracts produced from pickled and dried mustard in rapeseed and peanut oils. J Food Sci. 2012, 77: C394-C400.

  64. 64.

    Prasad N, Yang B, Kong KW, Khoo HE, Sun J, Azlan A, Ismail A, Romli ZB: Phytochemicals and Antioxidant Capacity from Nypa fruticans Wurmb. Fruit. Evid Based Complement Alternat Med. 2013, 2013: 154606-

  65. 65.

    Dawes HM, Keene JB: Phenolic composition of kiwifruit juice. J Agric Food Chem. 1999, 47: 2398-2403.

  66. 66.

    Godevac D, Tesevic V, Vajs V, Milosavljevic S, Zdunic G, Dordevic B, Stankovic M: Chemical composition of currant seed extracts and their protective effect on human lymphocytes DNA. J Food Sci. 2012, 77: C779-C783.

  67. 67.

    Huang WY, Zhang HC, Liu WX, Li CY: Survey of antioxidant capacity and phenolic composition of blueberry, blackberry, and strawberry in Nanjing. J Zhejiang Univ Sci B. 2012, 13: 94-102.

  68. 68.

    Memon AA, Memon N, Bhanger MI, Luthria DL: Assay of phenolic compounds from four species of ber (Ziziphus mauritiana L.) fruits: comparison of three base hydrolysis procedure for quantification of total phenolic acids. Food Chem. 2013, 139: 496-502.

  69. 69.

    Li J, Deng Y, Yuan C, Pan L, Chai H, Keller WJ, Kinghorn AD: Antioxidant and quinone reductase-inducing constituents of black chokeberry (Aronia melanocarpa) fruits. J Agric Food Chem. 2012, 60: 11551-11559.

  70. 70.

    Palafox-Carlos H, Gil-Chavez J, Sotelo-Mundo RR, Namiesnik J, Gorinstein S, Gonzalez-Aguilar GA: Antioxidant interactions between major phenolic compounds found in ‘Ataulfo’ mango pulp: chlorogenic, gallic, protocatechuic and vanillic acids. Molecules. 2012, 17: 12657-12664.

  71. 71.

    Masella R, Santangelo C, D’Archivio M, Li Volti G, Giovannini C, Galvano F: Protocatechuic acid and human disease prevention: biological activities and molecular mechanisms. Curr Med Chem. 2012, 19: 2901-2917.

  72. 72.

    Pacheco-Palencia LA, Mertens-Talcott S, Talcott ST: Chemical composition, antioxidant properties, and thermal stability of a phytochemical-enriched oil from Açai (Euterpe oleracea Mart.). J Agr Food Chem. 2008, 56: 4631-4636.

  73. 73.

    Poovarodom S, Haruenkit R, Vearasilp S, Namiesnik J, Cvikrová M, Martincová O, Ezra A, Suhaj M, Ruamuke P, Gorinstein S: Comparative characterization of durian, mango and avocado. Int J Food Sci Tech. 2010, 45: 921-929.

  74. 74.

    Gorinstein S, Leontowicz H, Leontowicz M, Namiesnik J, Najman K, Drzewiecki J, Cvikrová M, Martincová O, Katrich E, Trakhtenberg S: Comparison of main bioactive compounds and antioxidant activities in garlic and white and red onions after treatment protocols. J Agr Food Chem. 2008, 56: 4418-4426.

  75. 75.

    Koli R, Erlund I, Jula A, Marniemi J, Mattila P, Alfthan G: Bioavailability of various polyphenols from a diet containing moderate amounts of berries. J Agr Food Chem. 2010, 58: 3927-3932.

  76. 76.

    Zadernowski R, Czaplicki S, Naczk M: Phenolic acid profiles of mangosteen fruits (Garcinia mangostana). Food Chem. 2009, 112: 685-689.

  77. 77.

    Gruz J, Ayaz FA, Torun H, Strnad M: Phenolic acid content and radical scavenging activity of extracts from medlar (Mespilus germanica L.) fruit at different stages of ripening. Food Chem. 2011, 124: 271-277.

  78. 78.

    Liberatore L, Procida G, D’Alessandro N, Cichelli A: Solid-phase extraction and gas chromatographic analysis of phenolic compounds in virgin olive oil. Food Chem. 2001, 73: 119-124.

  79. 79.

    Buiarelli F, Cartoni G, Coccioli F, Levetsovitou Z: Determination of phenolic acids in wine by high-performance liquid chromatography with microbore column. J Chrom A. 1995, 695: 229-235.

  80. 80.

    Neveu V, Perez-Jiménez J, Crespy V, du Chaffaut L, Mennen L, Knox C, Eisner R, Cruz J, Wishart D, Scalbert A: Phenol-Explorer: An online comprehensive database on polyphenol contents in foods. Database (Oxford). 2010, 2010: doi:10.1093/database/bap024, 9 pages available at:

  81. 81.

    Manach C, Knox C, Eisner R, Wishart D, Scalbert A: Phenol-Explorer 3.0: a major update of the Phenol-Explorer database to incorporate data on the effects of food processing on polyphenol content. Database (Oxford). 2013, 2013: doi:10.1093/database/bat07, 8 pages available at:

  82. 82.

    Rothwell JA, Urpi-Sarda M, Boto-Ordoñez M, Knox C, Llorach R, Eisner R, Cruz J, Neveu V, Wishart D, Manach C, Andres-Lacueva C, Scalbert A: Phenol-Explorer-2: A major update of the Phenol-Explorer database integrating data on polyphenol metabolism and pharmacokinetics in humans and experimental animals. Database (Oxford). 2012, 2012: doi:10.1093/database/bas031, 8 pages available at:

  83. 83.

    Vari R, D’Archivio M, Filesi C, Carotenuto S, Scazzocchio B, Santangelo C, Giovannini C, Masella R: Protocatechuic acid induces antioxidant/detoxifying enzyme expression through JNK-mediated Nrf2 activation in murine macrophages. J Nutr Biochem. 2011, 22: 409-417.

  84. 84.

    Masella R, Vari R, D’Archivio M, Di Benedetto R, Matarrese P, Malorni W, Scazzocchio B, Giovannini C: Extra virgin olive oil biophenols inhibit cell-mediated oxidation of LDL by increasing the mRNA transcription of glutathione-related enzymes. J Nutr. 2004, 134: 785-791.

  85. 85.

    Harini R, Pugalendi KV: Antihyperglycemic effect of protocatechuic acid on streptozotocin-diabetic rats. J Basic Clin Physiol Pharmacol. 2010, 21: 79-91.

  86. 86.

    Liu C, Kuei C, Zhu J, Yu J, Zhang L, Shih A, Mirzadegan T, Shelton J, Sutton S, Connelly MA, Lee G, Carruthers N, Wu J, Lovenberg TW: 3,5-Dihydroxybenzoic acid, a specific agonist for hydroxycarboxylic acid 1, inhibits lipolysis in adipocytes. J Pharmacol Exp Ther. 2012, 341: 794-801.

  87. 87.

    Vogt A, Kassner U, Hostalek U, Steinhagen-Thiessen E: Prolonged-release nicotinic acid for the management of dyslipidemia: an update including results from the NAUTILUS study. Vasc Health Risk Manag. 2007, 3: 467-479.

  88. 88.

    Monagas M, Urpi-Sarda M, Sanchez-Patan F, Llorach R, Garrido I, Gomez-Cordoves C, Andres-Lacueva C, Bartolome B: Insights into the metabolism and microbial biotransformation of dietary flavan-3-ols and the bioactivity of their metabolites. Food Funct. 2010, 1: 233-253.

  89. 89.

    Takahama U, Hirota S: Deglucosidation of quercetin glucosides to the aglycone and formation of antifungal agents by peroxidase-dependent oxidation of quercetin on browning of onion scales. Plant Cell Physiol. 2000, 41: 1021-1029.

  90. 90.

    Pietta PG, Simonetti P, Gardana C, Brusamolino A, Morazzoni P, Bombardelli E: Catechin metabolites after intake of green tea infusions. Biofactors. 1998, 8: 111-118.

  91. 91.

    Vitaglione P, Donnarumma G, Napolitano A, Galvano F, Gallo A, Scalfi L, Fogliano V: Protocatechuic acid is the major human metabolite of cyanidin-glucosides. J Nutr. 2007, 137: 2043-2048.

  92. 92.

    Chen W, Wang D, Wang LS, Bei D, Wang J, See WA, Mallery SR, Stoner GD, Liu Z: Pharmacokinetics of protocatechuic acid in mouse and its quantification in human plasma using LC-tandem mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci. 2012, 908: 39-44.

  93. 93.

    Koli R, Erlund I, Jula A, Marniemi J, Mattila P, Alfthan G: Bioavailability of various polyphenols from a diet containing moderate amounts of berries. J Agric Food Chem. 2010, 58: 3927-3932.

  94. 94.

    de Ferrars RM, Cassidy A, Curtis P, Kay CD: Phenolic metabolites of anthocyanins following a dietary intervention study in post-menopausal women. Mol Nutr Food Res. 2013, 58: 490-502.

  95. 95.

    Na HK, Surh YJ: Modulation of Nrf2-mediated antioxidant and detoxifying enzyme induction by the green tea polyphenol EGCG. Food Chem Toxicol. 2008, 46: 1271-1278.

  96. 96.

    Dinkova-Kostova AT, Talalay P, Sharkey J, Zhang Y, Holtzclaw WD, Wang XJ, David E, Schiavoni KH, Finlayson S, Mierke DF, Honda T: An exceptionally potent inducer of cytoprotective enzymes: elucidation of the structural features that determine inducer potency and reactivity with Keap1. J Biol Chem. 2010, 285: 33747-33755.

Download references


This topic forms a component of a Grant in-aid of research from KACST, Saudi Arabia to Paul Ganguly.

Author information

Correspondence to Paul Ganguly.

Additional information

Competing interests

The authors declare that they have no competing interests.

Authors’ contributions

The concept for this paper was developed by PG. HJA, AMZA and BMHA did extensive literature research and wrote the first draft of the manuscript. BHJJ revised the manuscript, in particular adding background on Nrf2 activators and HCA activators. All authors read and approved the final manuscript.

Authors’ original submitted files for images

Below are the links to the authors’ original submitted files for images.

Authors’ original file for figure 1

Authors’ original file for figure 2

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark


  • Antioxidant enzymes
  • Atherosclerosis
  • Dyslipidemia
  • Hydroxycarboxylic acid receptors
  • Hypertension
  • Inflammation
  • Lipolysis
  • Nrf2
  • Phytochemicals
  • Oxidative stress
  • Dihydroxybenzoic acid
  • Cardiovascular diseases
  • Food products
  • Pharmacologically-active compounds